And yeah agree the FA addition is good to see, I don't think they would add that if they don't have a good feeling / first look at the pre-clinical findings of 434 in the FA stem cell model. The Reata omaveloxolone story is just too attractive to not pursue that avenue eventually.
On the poised for progress slide I still feel they can go further in explaining why SP is currently low - i.e. multiple years of funding RCT + open label + natural history studies. But now those costs are nearly all behind us with a huge catalyst moment upon us in just 6-10 weeks which could lead to a significant rerate if RCT results support progressing to a ph 3, or better the accelerated approval, as that is when partners would be most interested in joining and when we are interested in bringing partners/buyers on. Articulating this story could help us get through this $0.4c speedhump before the read-out. I might of said this before but does seem crazy we could head into the read-out with a $16m MC, if results are even half decent the upside is still huge, imagine if results are very good. All just my opinion of course.
Anyone going to AGM on Friday in Melbourne?
Cheers
ATH Price at posting:
0.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)